EA200100385A1 - Композиция и способ лечения нарушения гемостаза у субъекта (варианты) - Google Patents

Композиция и способ лечения нарушения гемостаза у субъекта (варианты)

Info

Publication number
EA200100385A1
EA200100385A1 EA200100385A EA200100385A EA200100385A1 EA 200100385 A1 EA200100385 A1 EA 200100385A1 EA 200100385 A EA200100385 A EA 200100385A EA 200100385 A EA200100385 A EA 200100385A EA 200100385 A1 EA200100385 A1 EA 200100385A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hemostasis
options
subject
treatment
composition
Prior art date
Application number
EA200100385A
Other languages
English (en)
Other versions
EA005236B1 (ru
Inventor
Гэри С. Грэй
Джиахуа Киан
Мэри Коллинс
Леон У. Хойэр
Original Assignee
Джинеткс Инститьют, Инк.
Эмерикэн Ред Кросс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинеткс Инститьют, Инк., Эмерикэн Ред Кросс filed Critical Джинеткс Инститьют, Инк.
Publication of EA200100385A1 publication Critical patent/EA200100385A1/ru
Publication of EA005236B1 publication Critical patent/EA005236B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Представлены композиции и способы лечения нарушений гемостаза с использованием агентов, которые стимулируют гемостаз, и агентов, которые ингибируют костимулирующий сигнал в Т-клетке. Данные композиции и способы дают возможность лечить нарушения гемостаза с использованием чужеродных терапевтических белков при отрицательной модуляции иммунных ответов на терапевтические белки.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100385A 1998-09-21 1999-09-21 Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты) EA005236B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (2)

Publication Number Publication Date
EA200100385A1 true EA200100385A1 (ru) 2001-10-22
EA005236B1 EA005236B1 (ru) 2004-12-30

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100385A EA005236B1 (ru) 1998-09-21 1999-09-21 Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты)

Country Status (21)

Country Link
EP (1) EP1115423A1 (ru)
JP (1) JP2002526455A (ru)
KR (1) KR20010085830A (ru)
CN (1) CN1331602A (ru)
AU (1) AU761206B2 (ru)
BR (1) BR9913991A (ru)
CA (1) CA2343916A1 (ru)
CZ (1) CZ20011021A3 (ru)
EA (1) EA005236B1 (ru)
HK (1) HK1039059A1 (ru)
HU (1) HUP0103960A3 (ru)
IL (1) IL142069A0 (ru)
LT (1) LT4920B (ru)
LV (1) LV12768B (ru)
MX (1) MXPA01002898A (ru)
NO (1) NO20011412L (ru)
NZ (1) NZ511034A (ru)
PL (1) PL346796A1 (ru)
SI (1) SI20626A (ru)
WO (1) WO2000016801A1 (ru)
ZA (1) ZA200103156B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU6173501A (en) * 2000-05-19 2001-12-03 Blood Res Center Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
JP2007516509A (ja) * 2003-06-10 2007-06-21 スミスズ ディテクション インコーポレイティド センサ装置
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
TR199903141T2 (xx) * 1997-06-20 2000-09-21 Biogen, Inc. Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.
US8082673B2 (en) 2009-11-06 2011-12-27 Hexagon Metrology Ab Systems and methods for control and calibration of a CMM

Also Published As

Publication number Publication date
KR20010085830A (ko) 2001-09-07
AU761206B2 (en) 2003-05-29
WO2000016801A9 (en) 2000-10-26
NZ511034A (en) 2004-03-26
LV12768B (lv) 2002-06-20
NO20011412D0 (no) 2001-03-20
MXPA01002898A (es) 2002-06-04
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
HUP0103960A3 (en) 2003-09-29
PL346796A1 (en) 2002-02-25
NO20011412L (no) 2001-05-16
AU6057899A (en) 2000-04-10
LV12768A (en) 2001-12-20
LT4920B (lt) 2002-06-25
EP1115423A1 (en) 2001-07-18
LT2001045A (en) 2002-01-25
WO2000016801A1 (en) 2000-03-30
HUP0103960A2 (hu) 2002-02-28
IL142069A0 (en) 2002-03-10
HK1039059A1 (zh) 2002-04-12
CN1331602A (zh) 2002-01-16
SI20626A (sl) 2002-02-28
ZA200103156B (en) 2002-07-18
EA005236B1 (ru) 2004-12-30
CA2343916A1 (en) 2000-03-30
BR9913991A (pt) 2001-07-03

Similar Documents

Publication Publication Date Title
EA199801044A1 (ru) Модуляторы регенерации тканей
DE3751470T2 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69316948T2 (de) Lösliche Liganden für CD40
FI844510A0 (fi) Ensym-resistenta immunsystemet modulerande peptider.
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE286392T1 (de) Photodynamische behandlung von synovium
BR9607894A (pt) Processo para tratar tumores
ATE245030T1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
ATE74282T1 (de) Methode zur behandlung von plasma und dessen produkten.
DE69703689T2 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
EA200100385A1 (ru) Композиция и способ лечения нарушения гемостаза у субъекта (варианты)
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE69319341T2 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU